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Introduction: The effects of short course of corticosteroids on the metabolic processes and bone
formation has not been well studied. Our aim was to compare the efficacy, the side effects and
the bone and lipid metabolisms in IBD patients using bolus or conventional tapering of
methylprednisolone for 12 weeks.
Patients and methods: Nineteen IBD patients received intravenous methylprednisolone of 0161 mg/kg for 5 days tapered by 4 mg per week. Patients were prospectively randomized in two
groups. In “conventional” group (I) steroids were given daily. In “pulse” group (II) weekly doses
of steroids were given on special days of the week. The body mass index (BMI) was measured
before and after the corticosteroid therapy. Blood samples were collected to assess glucose
level, electrolytes, cholesterol and triglyceride levels, inflammatory parameters, cortisol,
osteocalcin and crosslaps values. Total body composition analysis was performed at the
beginning and at the end of the steroid therapy.dy design, data collection, supervision of patient selection and manuscript preparation: Klaudia Farkas,
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993Bolus administration of steroid therapy is more favorable than the conventional useResults: In Group I, BMI increased, total body bone density decreased significantly at the end of
the steroid therapy. Body fat percent showed a tendency to be higher at the end of steroid
therapy in Group I. Cholesterol level increased significantly in Group I patients. The decrease in
serum cortisol level was more remarkable in Group I vs. Group II after steroid therapy. Less
side-effect occurred in Group II vs. Group I.
Discussion: Our results suggest that bolus tapering of corticosteroids may have more favorable
short term outcome than conventional tapering that may revolutionize steroid therapy in IBD.






Corticosteroids still have an important role in the manage-
ment of acute episodes of inflammatory bowel disease
(IBD-Crohn's disease [CD], ulcerative colitis [UC]). Parenter-
al corticosteroids are usually the first treatment of choice
for hospitalized patients with severe UC and CD.1 However,
use of steroids is associated with some well-known potential
harmful side-effects; therefore oral steroids are recom-
mended to be gradually tapered off and discontinued after
12 weeks in case of appropriate response to the parenteral
therapy. Corticosteroid therapy is known to contribute to
changes in body composition with the alteration of protein
synthesis and degradation in skeletal muscle, resulting in
decreased muscle mass and reduced fat-free mass. Steroids
also lead to a reduction in the total body bone mineral
density (BMD).2 Therefore total body composition analysis is
a useful method for quantification of multiple whole body
and regional components, including bone mineral, fat, and
lean soft tissue in patients treated with steroids. It gives a
direct measurement of the percent body fat, muscle and
bone (in grams) for the entire body and sub regions like the
arm, leg, and trunk.
The optimal dose response for parenteral steroids in the
treatment of severe attacks has not been clarified yet;
dosages of methylprednisolone 40–60 mg or 1 mg/kg per
day orally are the most frequently used regimen1,3 for
flare up. Furthermore, no randomized trials have studied
and even no guidelines have been developed by the
European Crohn's and Colitis Organisation on taper sched-
ules. After the induction of remission, methylprednisolone
is usually tapered 8–16 mg weekly until a daily dose of
32 mg is reached followed by a tapering of 4 mg/week.
Tapering steroid regimen is most frequently carried out by
administrating the drug daily, although alternate-day
steroid management (given every other day) has also
been a widely employed and effective mode of therapy for
ages associating with fewer unpleasant side effects.4 The
efficacy of “bolus-administered” corticosteroids when
weekly dose of steroid regimen is given on special days
has not been previously examined in patients with IBD. The
effect of a “short-term” 12-week course of corticosteroids
on the metabolic processes and bone formation has not
been well studied too; although these are some of the most
important side effects should be considered.
The aim of the present pilot study was to compare the
efficacy, the frequency of side effects and the changes in
bone and lipid metabolism in IBD patients using bolus or
conventional tapering of methylprednisolone for 12 weeks.2. Patients and methods
2.1. Study design and patients
This single-center, prospective, randomized trial was carried
out from November 2011 to February 2013 on consecutive
patients with acute exacerbation of IBD and not being on
steroid therapy admitted to our clinic. Diagnosis was based on
the Lennard-Jones criteria.5 Crohn's disease phenotype was
determined according to the Montreal classification.6 Clinical
activities were determined by Crohn's Disease Activity Index
(CDAI)7 in CD and by partial Mayo score8 in UC. Twenty
patients were enrolled in the study. The median CDAI and
partial Mayo score were 184 and 6 in CD and UC at the time of
the enrolment. None of the patients received oral corticoste-
roid at the time or at least 6 months before the enrolment. On
admission a complete blood chemistry including erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), serum
glucose, electrolytes, liver and renal function, cholesterol,
triglycerides, blood count, serum cortisol, calcium, dehydro-
epiandrosterone (DHEA), thyroid stimulating hormone (TSH),
parathyroid hormone (PTH),β-crosslaps and osteocalcin levels
were performed before starting steroid therapy. The mean
value of CRP, ESR, leukocytes and thrombocytes before
steroid therapy were 16 mg/l, 21.5 mm/h, 8.828 G/l and
322 G/l. Flexible colonoscopy or sigmoidoscopy with biop-
sies was carried out only in patient with relevance to
therapy, however, it was not essential for inclusion into the
trial. Thus, 3 CD and 13 UC patients underwent colonoscopy
at inclusion. DXA total body composition analysis was also
performed at the beginning of the study to determine the
fat and fat-free component of the body.
Patients eligible for iv. steroid therapy received methyl-
prednisolone dosage 1 mg/kg for 5 days. After iv. therapy,
patients were prospectively randomized in two groups. In
“conventional” group (Group I) methylprednisolone was
given daily while in “bolus-administered” group (Group II)
weekly dose of steroids was given on special days of the week.
64 mg/daymethylprednisolone dose at the first week in Group
I was equal to 150 mg/day given in the first 3 days in Group II.
Finally, both groups received the same methylprednisolone
dose and it was tapered by 4 mg per week in both groups. The
two different types of methylprednisolone dosages are
detailed in Table 1. Follow-up appointments were done
every two weeks. These visits involved the assessment of
the clinical activities by the determination of CDAI and
pMayo scores. Patients were asked about side effects, the
body mass index was determined and the waist and hip
circumferences were also measured. Laboratory assessment
Table 1 Methylprednisolone dosages in the conventional
and the bolus administration groups.
Week/day 1 2 3 4 5 6 7 Total dose
Conventional administration
1 64 64 64 64 64 64 64 448
2 48 48 48 48 48 48 48 336
3 32 32 32 32 32 32 32 224
4 28 28 28 28 28 28 28 196
5 24 24 24 24 24 24 24 168
6 20 20 20 20 20 20 20 140
7 16 16 16 16 16 16 16 112
8 12 12 12 12 12 12 12 84
9 8 8 8 8 8 8 8 56
10 4 4 4 4 4 4 4 28
11 2 2 2 2 2 2 2 14
12 0 0 0 0 0 0 0 0
Bolus administration
1 150 0 150 0 150 0 0 450
2 112 0 112 0 112 0 0 336
3 75 0 75 0 75 0 0 225
4 98 0 98 0 0 0 0 196
5 84 0 84 0 0 0 0 168
6 70 0 70 0 0 0 0 140
7 112 0 0 0 0 0 0 112
8 84 0 0 0 0 0 0 84
9 56 0 0 0 0 0 0 56
10 28 0 0 0 0 0 0 28
11 12 0 0 0 0 0 0 12
12 0 0 0 0 0 0 0 0





Mean age at the diagnosis (years) 34.3 30.3




– Ileal 1 2
– Colonic 2 1
– Ileocolonic – –
– Extensive colitis 3 5
– Left-sided colitis 3 2
– Proctitis – –
Concomitant therapy
– 5-ASA 4 6
– Budesonide 0 2
– Azathioprine 3 4
– Metronidazole 2 1
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 (including inflammatory parameters, electrolytes, glucose
level, liver and renal function, and blood count) was carried
out every four weeks. Detailed laboratory parameters
(DHEA, TSH, PTH, serum cortisol, serum β-crosslaps and
osteocalcin levels) and DXA for total body composition
analysis were performed at week 0 and week 12. Clinical
remission was defined as a CDAI of b150 points and a Mayo
score of b2 points. The study was approved by the Regional
and Institutional Human Medical Biological Research Ethics
Committee of the University of Szeged (Number: 74/2011).
2.2. End points
The primary end point of the study was the comparison of
the efficacy of the conventional and the bolus-administered
corticosteroid therapy and also the assessment of their
effects on the adrenal glands hormone secretion and on the
lipid and bone metabolisms. Secondary end points were the
frequency of steroid-related side effects in the two groups.
2.3. Statistical analysis
Student's t-test was employed to compare continuous
variables. Multivariate analysis with stepwise logistic re-
gression by SPSS software was performed to investigate the
parameters with a possible influence on clinical outcome,
such as age, gender, location of disease, duration of disease,concomitant immunosuppressive therapy. The differences
between the two groups were performed by mixed effects
ANOVA model for repeated measures. The results were
corrected using a Bonferroni–Holm method for multiple
testing. A p value less than 0.05 was considered statistically
significant.3. Results
3.1. Patient characteristics, clinical response
During the study period, 20 patients with IBD (5 with CD, 15
with UC) were enrolled. At day 5, all but one patient
achieved clinical remission. One patient proved to be
refractory to intravenous steroid and needed rescue
therapy therefore she was excluded because of treatment
failure. Methylprednisolone was tapered weekly and
stopped at week 12 in these 19 patients who could complete
the study. The clinical characteristics of the participated
19 patients are presented in Table 2. Ten patients had
already been diagnosed with IBD, while the remaining 9
patients were at disease onset. Although the male/female
ratio was higher in Group II, baseline clinical characteristics
of patients did not differ significantly between the two
treatment groups. CDAI and pMayo score showed decreasing
pattern in both groups during the steroid therapy. CDAI and
pMayo score decreased to a median value of 21 and 0
(median CDAI 35, median partial Mayo score 0 in Group I and
12 and 0 in Group II) at the end of the steroid therapy.
Median CDAI and pMayo scores during the “conventional”
and the “bolus” methylprednisolone treatment periods are
indicated in Table 3. The mean values of CRP, ESR,
leukocytes and thrombocytes after steroid therapy were
7.4 mg/l, 9.7 mm/h, 7.935 G/l and 238 G/l. The effects of
bolus therapy on the clinical and laboratory parameters of
disease activity did not differ from the conventional
administration. The patients in both groups had not
relapsed at the discontinuation of steroid therapy.
Table 3 Median CDAI and pMayo scores during the
“conventional” and the “bolus” methylprednisolone treat-
ment periods.









0 204 6.2 164 5.1
2 184 5 152 4
4 146 3.4 126 2
6 86 1 90 0
8 72 0 64 0
10 68 0 48 0
12 35 0 12 0
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 3.2. Changes in adrenal glands hormone secretion,
in the lipid and bone metabolism after methylpred-
nisolone therapy
In Group I, BMI increased significantly at the end of the
steroid therapy (p = 0.008). In Group II, no difference was
observed in BMI before and after the steroid therapy. Total
body composition analysis showed significant decrease in
bone density in Group I (p = 0.032). Body fat percent showed
a tendency to be higher at the end of steroid therapy in
Group I, although the difference was not significant.
Considering the laboratory parameters, serum cholesterol
level increased significantly in Group I patients after steroid
therapy (p = 0.028). The decrease in serum cortisol level was
more remarkable in Group I vs. Group II after steroid therapy
(p = 0.02 and p = 0.055). Fig. 1 summarizes the significant
changes in the examined parameters.
No changes were detected in the waist and hip circumfer-
ence, T and Z scores, electrolytes, liver and renal function,Figure 1 Significant changes in the examined parameters aftserum glucose, serum calcium, triglyceride, DHEA, TSH, PTH
and β-crosslaps before and after the steroid therapy neither in
Group I, nor in Group II.
3.3. Steroid-related side effects
The most common side effects occurring during the
therapy were the Cushingoid appearance, development
of acne, fatigue, gastrointestinal complaints. Side effects
were presented in 5/9 (55.6%) vs. 4/10 (40%) of the patient
in Groups I and II. Cushingoid appearance did not occur in
Group II. The side effects are summarized in Table 4.
4. Discussion
This prospective study revealed that “bolus-administered”
corticosteroid therapy was as effective as the conventional
administration of the drug, but had less harmful effects on
bone and lipid metabolims and was associated with fewer
side effects than the previous one. Significant increase in
BMI and serum cholesterol level and decrease in body density
were shown when methylprednisolone was tapered conven-
tionally, compared to the bolus administration of the drug.
Body fat percent also showed a tendency to be higher at the
end of steroid therapy in patients using the conventional
tapering regimens. Cushingoid appearance also occurred
only in patients on conventional administration.
For the past 30 years, corticosteroids have been the
mainstay of therapy in patients with moderate to severe
active IBD.9 Intravenous therapy generally produces rapid
improvement of symptoms. Once improvement has been
achieved, corticosteroids should be tapered gradually per
week until the drug is discontinued. The mean goal of IBD
therapy is to decrease the steroid-related side-effects and
to minimize steroid dependency with the development of
new series of anti-inflammatory glucocorticoids wither 12-week methylprednisolone therapy in Groups I and II.
n June 23, 2016




Patient 1 Cushingoid appearance
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 enhanced topical potency and less systemic activity such as
budesonide or beclamethasone.10 Less attention is paid to
the dosing of steroids, although it seems to be also
important.
Although there are no trials between different steroid-
tapering regimens, the goal in the daily practice is to get
patients off corticosteroids within 12 weeks and maintain
disease remission. Alternatively, alternate-day corticosteroid
therapy can also be used in patients with refractory Crohn's
disease — even for longer time.11 However, some available
evidence suggested that themanner of corticosteroid tapering
probably did not change the long term outcome in IBD.12
Use of “bolus-administered” steroids is a novel possibility
to optimize the therapy. Bolus administration is actually
an untested manner that has been anecdotally recognized
to be more effective than the conventional use of steroid
therapy. Multiple doses of steroids were previously shown
to cause more adverse effects than a single dose.13 In a
single-center, double-blind trial performed by Bossa et
al., patients with a severe attack of UC were scheduled to
receive equal iv. doses of methylprednisolone, randomly
given as either a bolus injection administered twice daily
or continuous infusion.14 Methylprednisolone given as a
continuous infusion was no better than bolus administration in
terms of efficacy and safety. The aim of bolus steroid therapy
is to get quicker and stronger anti-inflammatory effect. Giving
a higher dose of methylprednisolone, an immediate profound
anti-inflammatory effect is supposed to be achieved with
lower toxicities and no prolonged suppressive effect on the
hypothalamic–pituitary axis.
Our results did not show any significant difference
according to the disease outcome between the two
administration types at the end of the therapy and at follow
up times for any of the clinical or laboratory parameters
measured, confirming the same efficacy of bolus therapy as
in case of conventional administration.The widespread use of corticosteroids has been associ-
ated with an increased incidence of a variety of adverse
effects involving the musculoskeletal, the endocrine, the
metabolic system, the neuropsychiatric wellbeing, the GI
system, the skin, the eyes, the infectious risk, the
cardiovascular and the hematological system.12 Dosage
and duration of therapy are some of the most important
factors influencing the development of the toxic effects of
corticosteroids. Although no data is available on the
harmful effects of short term corticosteroid therapy on
lipid and bone metabolism, our results revealed that
short-term use of steroids increases BMI and body fat
percent and decrease bone density. Common adverse
effects of short term therapy include moon face, mood
changes, insomnia, GI intolerance, weakness, fluid retention,
weight gain, increased appetite, increased infections, amen-
orrhea, elevated blood glucose, slow wound healing, striae,
and acneiform rash. Alternate-day steroid therapy may
decrease hypothalamic–pituitary–adrenal axis suppression
and therefore the development of certain side effects.15
However, in this study, the most common side effects
occurred more frequently in patients with conventional vs.
bolus-administration steroid therapy.
Osteoporosis is present in 30–45% of patients with CD,
and its rate is somewhat lower in patients with UC.15,16
Osteopenia is likely related to the chronic inflammatory
process itself, and furthermore triggered by steroid use.
Steroid related osteoporosis is multifactorial; decreased
calcium absorption, development of secondary hyperpara-
thyroidism, stimulating osteoclast activity, and decrease
osteoblast production are only some of the potential
etiological factors.17 Hyperlipidemia is also a common side
effect of steroid therapy.18 Steroids are supposed to
influence lipid metabolism by redistributing body fat and
facilitating of effects of lipolytic agents. Large doses of
glucocorticoids lead to redistribution of fat to the upper
trunk and face, with a concomitant loss of fat in the
extremities.19 Our result revealed beneficial effect of
bolus-administered corticosteroid therapy on bone density
and body fat percent.
The main limitation of this pilot study is the low
number of participating patients. This is mainly due to the
relatively high costs of total body composition analysis,
which is used for the accurate determination of the
various body weight components: fat mass, fat-free
mass, total body water and bone mass.20 However, use
of total body composition analysis gives a valuable part of
this prospective randomized study, since the alterations
of bone and lipid metabolisms could be examined in a
parallel way.
In conclusion, this single-center study suggests that bolus
tapering of equivalent doses of methylprednisolone admin-
istered in conventional daily doses has equivalent clinical
efficacy, but more favorable side effect profile. As no
significant difference was detected between the two
administration types on the clinical and laboratory param-
eters of disease activity, it appears that bolus administra-
tion of corticosteroids can safely and effectively replace the
conventional use of methylprednisolone for active IBD. Of
course, further controlled, randomized trials are needed to
confirm these results that may revolutionize steroid therapy
in IBD.
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